Perspectives in central nervous system malignancies.
Stummer
Walter
W
Heinrich Heine University of Dusseldorf, Universitatsstrasse 1, 40595 Dusseldorf, Germany. wstummer@uni-duesseldorf.de
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000532:radiotherapy; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D000077156:Gefitinib; D005910:Glioma / Q000188:drug therapy* / Q000201:enzymology / Q000532:radiotherapy; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011494:Protein Kinases / Q000378:metabolism; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; C401859:temsirolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D066246:ErbB Receptors; D058570:TOR Serine-Threonine Kinases; D011493:Protein Kinase C; D000077156:Gefitinib; C504878:enzastaurin; D020123:Sirolimus